Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis

References

• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–96
   PubMed Web of Science ®Google Scholar
• Perfetto F, Cappelli F, Bergesio F, Ciuti G, Porciani MC, Padeletti L, Moggi Pignone A. Cardiac amyloidosis: the heart of the matter. Intern Emerg Med 2013;8:191–203
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203–12
   PubMed Web of Science ®Google Scholar
• Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003;107:2446–52
   PubMed Web of Science ®Google Scholar
• Porciani MC, Lilli A, Perfetto F, Cappelli F, Massimiliano Rao C, Del Pace S, Ciaccheri M, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid 2009;16:63–70
   PubMed Web of Science ®Google Scholar
• Porciani MC, Cappelli F, Perfetto F, Ciaccheri M, Castelli G, Ricceri I, Chiostri M, et al. Rotational mechanics of the left ventricle in AL amyloidosis. Echocardiography 2010;27:1061–8
   PubMed Web of Science ®Google Scholar
• Bellavia D, Pellikka PA, Dispenzieri A, Scott CG, Al-Zahrani GB, Grogan M, Pitrolo F, et al. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. Eur Heart J Cardiovasc Imaging 2012;13:680–9
   PubMed Web of Science ®Google Scholar
• Cappelli F, Porciani MC, Bergesio F, Perlini S, Attanà P, Moggi Pignone A, Salinaro F, et al. Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging 2012;13:416–22
   PubMed Web of Science ®Google Scholar
• Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440–5
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–7
   PubMed Web of Science ®Google Scholar
• Choi HS, Kim KH, Yoon HJ, Hong YJ, Kim JH, Ahn Y, Jeong MH, et al. Usefulness of cardiac biomarkers in the prediction of right ventricular dysfunction before echocardiography in acute pulmonary embolism. J Cardiol 2012;60:508–13
   PubMedGoogle Scholar
• Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202–8
   PubMed Web of Science ®Google Scholar
• Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010;17:48–9
   Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70
   PubMed Web of Science ®Google Scholar
• Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002;15:67–84
   Google Scholar
• Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function: a study in normals and dilated cardiomyopathy. J Cardiol 1995;26:357–66
   PubMedGoogle Scholar
• Rudski LG, Lai WW, Afilalo J, Hua L, Handshumacher MD, Chandrasekaran K, Solomon SD. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography: endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology and the Canadian Society of Echocardiography Inizio modulo. J Am Soc Echocardiogr 2010;23:685–713
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, McConnell JP, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787–9
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–7
   PubMed Web of Science ®Google Scholar
• Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854–8
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989–95
   PubMed Web of Science ®Google Scholar
• Ghio S, Perlini S, Palladini G, Marsan NA, Faggiano G, Vezzoli M, Klersy C, et al. Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Fail 2007;9:808–13
   PubMed Web of Science ®Google Scholar
• Kim WH, Otsuji Y, Yuasa T, Minagoe S, Seward JB, Tei C. Evaluation of right ventricular dysfunction in patients with cardiac amyloidosis using Tei index. J Am Soc Echocardiogr 2004;17:45–9
   PubMedGoogle Scholar
• McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–69
   PubMed Web of Science ®Google Scholar
• Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, Obici L, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012;87:465–71
   PubMed Web of Science ®Google Scholar
• Capone R, Amsterdam EA, Mason DT, Zelis R. Systemic amyloidosis, functional coronary insufficiency and autonomic impairment. Ann Intern Med 1972;76:599–603
   PubMed Web of Science ®Google Scholar
• Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3:155–64
   PubMed Web of Science ®Google Scholar